Mandeep Dhalla, MD
Retina Specialist · Fort Lauderdale, FLNPI 1457389447
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,200 of the $12,986 with a category attached, or 78.5%. Genentech USA, Inc. accounts for 94.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $12,019 and has fallen 95.5% since, to $541 in 2025.
Across 44 payments — averaging $295.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$12K
- Regeneron Healthcare Solutions, Inc.$258
- Harrow Eye, LLC$125
- Apellis Pharmaceuticals, Inc.$112
- AbbVie$84
- Astellas Pharma US Inc$67
- plus $96 from 3 others
What the payments were for
- Speaking & faculty fees$10,20079%
- Travel & lodging$1,0008%
- Food & beverage$1,78514%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 24 | $12,243 |
| Regeneron Healthcare Solutions, Inc. | 6 | $258 |
| Harrow Eye, LLC | 1 | $125 |
| Apellis Pharmaceuticals, Inc. | 4 | $112 |
| AbbVie | 3 | $84 |
| Astellas Pharma US Inc | 2 | $67 |
| Novartis | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Viiv Healthcare Company | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,986 in reported general payments places this provider in the 75th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 24 | $2,962 |
| Prednisolone Acetate | 35 | $1,577 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $285 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 11 | $90 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Fort Lauderdale
- Sunil GuptaPensacola$1.8M
- Joseph NezgodaWest Palm Beach$600K
- Eduardo UchiyamaFt Lauderdale$356K
- Thomas AlbiniMiami$281K
- Audina BerrocalMiami$210K
- Philip RosenfeldMiami$206K
- John MyersPensacola$152K
- Timothy MurraySouth Miami$133K
- Adiel SmithAventura$116K
- Paul GalloglyPalm Beach Gardens$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.